Bifogade filer
Sprint Bioscience’s CFO Mathias Skalmstad leaves the company
Kurs
-1,67%
Likviditet
0,23 MSEK
Prenumeration
Kalender
| Tid* | ||
| 2025-02-12 | 07:30 | Bokslutskommuniké 2024 |
| 2024-10-30 | - | Kvartalsrapport 2024-Q3 |
| 2024-08-28 | - | Kvartalsrapport 2024-Q2 |
| 2024-05-10 | - | X-dag ordinarie utdelning SPRINT 0.00 SEK |
| 2024-05-08 | - | Årsstämma |
| 2024-05-08 | - | Kvartalsrapport 2024-Q1 |
| 2024-02-14 | - | Bokslutskommuniké 2023 |
| 2023-10-25 | - | Kvartalsrapport 2023-Q3 |
| 2023-08-24 | - | Kvartalsrapport 2023-Q2 |
| 2023-05-11 | - | X-dag ordinarie utdelning SPRINT 0.00 SEK |
| 2023-05-10 | - | Årsstämma |
| 2023-05-10 | - | Kvartalsrapport 2023-Q1 |
| 2023-02-15 | - | Bokslutskommuniké 2022 |
| 2022-10-26 | - | Kvartalsrapport 2022-Q3 |
| 2022-10-25 | - | Extra Bolagsstämma 2022 |
| 2022-08-24 | - | Kvartalsrapport 2022-Q2 |
| 2022-05-12 | - | X-dag ordinarie utdelning SPRINT 0.00 SEK |
| 2022-05-11 | - | Årsstämma |
| 2022-05-11 | - | Kvartalsrapport 2022-Q1 |
| 2022-02-16 | - | Bokslutskommuniké 2021 |
| 2021-10-27 | - | Kvartalsrapport 2021-Q3 |
| 2021-08-25 | - | Kvartalsrapport 2021-Q2 |
| 2021-07-21 | - | Extra Bolagsstämma 2021 |
| 2021-05-14 | - | X-dag ordinarie utdelning SPRINT 0.00 SEK |
| 2021-05-12 | - | Årsstämma |
| 2021-05-12 | - | Kvartalsrapport 2021-Q1 |
| 2021-02-17 | - | Bokslutskommuniké 2020 |
| 2020-10-28 | - | Kvartalsrapport 2020-Q3 |
| 2020-08-26 | - | Kvartalsrapport 2020-Q2 |
| 2020-05-14 | - | X-dag ordinarie utdelning SPRINT 0.00 SEK |
| 2020-05-13 | - | Årsstämma |
| 2020-05-13 | - | Kvartalsrapport 2020-Q1 |
| 2020-02-19 | - | Bokslutskommuniké 2019 |
| 2019-10-23 | - | Kvartalsrapport 2019-Q3 |
| 2019-08-22 | - | Kvartalsrapport 2019-Q2 |
| 2019-05-16 | - | X-dag ordinarie utdelning SPRINT 0.00 SEK |
| 2019-05-15 | - | Årsstämma |
| 2019-05-15 | - | Kvartalsrapport 2019-Q1 |
| 2019-02-20 | - | Bokslutskommuniké 2018 |
| 2018-10-24 | - | Kvartalsrapport 2018-Q3 |
| 2018-08-15 | - | Kvartalsrapport 2018-Q2 |
| 2018-05-17 | - | X-dag ordinarie utdelning SPRINT 0.00 SEK |
| 2018-05-16 | - | Årsstämma |
| 2018-05-16 | - | Kvartalsrapport 2018-Q1 |
| 2018-02-07 | - | Bokslutskommuniké 2017 |
| 2018-02-06 | - | Extra Bolagsstämma 2017 |
| 2017-11-15 | - | Kvartalsrapport 2017-Q3 |
| 2017-08-23 | - | Kvartalsrapport 2017-Q2 |
| 2017-05-18 | - | X-dag ordinarie utdelning SPRINT 0.00 SEK |
| 2017-05-17 | - | Årsstämma |
| 2017-05-17 | - | Kvartalsrapport 2017-Q1 |
| 2017-02-22 | - | Bokslutskommuniké 2016 |
| 2016-12-02 | - | Extra Bolagsstämma 2016 |
| 2016-11-16 | - | Kvartalsrapport 2016-Q3 |
| 2016-08-24 | - | Kvartalsrapport 2016-Q2 |
| 2016-05-19 | - | X-dag ordinarie utdelning SPRINT 0.00 SEK |
| 2016-05-18 | - | Årsstämma |
| 2016-05-18 | - | Kvartalsrapport 2016-Q1 |
| 2016-02-24 | - | Bokslutskommuniké 2015 |
| 2015-11-18 | - | Kvartalsrapport 2015-Q3 |
| 2015-08-26 | - | Kvartalsrapport 2015-Q2 |
| 2015-05-21 | - | X-dag ordinarie utdelning SPRINT 0.00 SEK |
| 2015-05-20 | - | Årsstämma |
| 2015-02-26 | - | Bokslutskommuniké 2014 |
| 2014-11-14 | - | Kvartalsrapport 2014-Q3 |
Beskrivning
| Land | Sverige |
|---|---|
| Lista | First North Stockholm |
| Sektor | Hälsovård |
| Industri | Bioteknik |
Sprint Bioscience AB (publ) announces that Mathias Skalmstad has decided to step down from his position as CFO to take on a new role at another company.
A recruitment process to find his successor will now begin. Mathias will remain at Sprint Bioscience during his three-month notice period.
For further information, kindly contact:
Johan Emilsson, CEO, Sprint Bioscience
Tel: +46 (8) 411 44 55
Epost:johan.emilsson@sprintbioscience.com
About Sprint Bioscience AB (publ)
Sprint Bioscience develops small molecule first-in-class drug programs with a focus on oncology. With a fragment-based drug development method, the company develops drug programs in a time- and resource-efficient manner. The programs are out-licensed to global pharmaceutical companies during the pre-clinical phase and the company has successfully entered into several license agreements. The Sprint Bioscience share is listed on the Nasdaq First North Premier Growth Market and trades under the ticker symbol SPRINT. The company is based in Stockholm with operations located in Huddinge. Further information is available on the company's website; www.sprintbioscience.com. Certified Advisor is FNCA Sweden AB, www.fnca.se.